Russian Direct Investment Fund (RDIF) and Hualan Biological Bacterin Inc. Hualan Biological Engineering Inc., one of the leading biopharmaceutical companies and the largest manufacturer of influenza vaccine in the PRC), announced an agreement of producing in China more than 100 million doses per year of the Sputnik V vaccine.
The volume produced will provide vaccination for more than 50 million people. RDIF and Hualan Biological Bacterin are focused on long-term collaboration.
“The partnership agreement with Hualan Biological Bacterin, one of the leading vaccine manufacturers in China, will significantly expand the production capacity for the production of Sputnik V. China is one of the main partners in the production of Russian vaccine, which is already used in all regions of the world to protect human health and has proven its high efficiency and safety, “said Kirill Dmitriev, CEO of the RDIF.
The Sputnik V vaccine is registered in 60 countries with a total population of 3 billion people. The effectiveness of Sputnik V is 91.6%, as confirmed by the publication of data in The Lancet, one of the oldest and most respected medical journals in the world.
